Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Head and Neck Squamous Cell Carcinoma|Non Small Cell Lung Cancer|Hepatocellular Cancer|Colorectal Cancer|Gastric Adenocarcinoma|Melanoma|Advanced Cancer
Interventions: DRUG: TTI-101|DRUG: TTI-101
Sponsor: Tvardi Therapeutics, Incorporated
Collaborators: M.D. Anderson Cancer Center